LAB Q2 2024 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$22M-18.7% YoY

Gross Profit

$10M46.1% margin

Operating Income

-$30M-134.5% margin

Net Income

-$46M-203.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-50.6%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$709M

Total Liabilities

$198M

Stockholders' Equity

$510M

Cash & Equivalents

$270M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$28M	-18.7%
Gross Profit	$10M	$14M	-23.7%
Operating Income	-$30M	-$17M	-73.4%
Net Income	-$46M	-$17M	-168.3%

Revenue Segments

Product And Service

$36M41%

Product

$22M25%

Service

$14M16%

Consumables

$9M10%

Instruments

$7M8%

Collaboration and Other Revenue

$989,0001%

Geographic Segments

Americas

$20M53%

EMEA

$11M28%

Asia Pacific

$7M18%